Last Updated on November 9, 2025 by The Health Master
NPPA
Download NPPA notification No. S.O. 4170(E) dt 15-09-2025, the link is given below: The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 9 formulations under the Drugs (Prices Control) Order, 2013, vide S.O. 4170 (E) dt 15-09-2025 based on the decision of 137th Authority meeting dated 15-09-2025.
The notification states as follows:
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
A table is given below the article
Note:
(a) The manufacturer of the above-mentioned formulations, i.e., the “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have actually paid it or it is payable to the Government on the retail price mentioned in column (6) of the above-mentioned table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013.
The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above, i.e., those who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to the fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes or rules, including manufacturing license permission from the competent authority, i.e., the central or state licensing authority, as may be applicable, by the concerned manufacturer/marketing company.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per the instant price notification and notes specified hereinabove, then the concerned manufacturer / marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of the manufacturer and marketing company specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer and marketing company Companies as specified in corresponding entries in Columns (2), (3), and (5) thereof, if any, issued prior to this notification, stand superseded.
Latest on National Pharmaceutical Pricing Authority (NPPA)
Latest notifications – DPCO / NPPA
NPPA updated price lists: Download
Latest Notifications: EC Act (Essential Commodities Act)
USFDA issued Form 483 to Reddy’s with 5 observations: Hyderabad
USFDA approval granted for blood clotting drug: Alembic
USFDA puts import Alert on Sun Pharma: Halol
Indian Drug Regulation Goes 97% Digital: CDSCO
5 Northern State SDCs Unite Against Counterfeit Drugs
USFDA issued Form 483 to Biocon with 5 observations
USFDA issued Form 483 to Aurobindo with 8 observations
Drug recall: Unichem recalls Cyclobenzaprine HCL Tablets
Table
| Sl. No. | Medicine | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | Aceclofenac, Paracetamol & Thiocolchicoside Tablets | Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg Thiocolchicoside IP 8 mg | 1 Tablet | M/s Innova Captab Ltd. / M/s Macleods Pharmaceuticals Ltd. | 27.49 |
| 2 | Aceclofenac, Paracetamol & Thiocolchicoside Tablets | Each film coated tablet contains: Aceclofenac IP 100 mg Paracetamol IP 325 mg Thiocolchicoside IP 4 mg | 1 Tablet | M/s Innova Captab Ltd. / M/s Macleods Pharmaceuticals Ltd. | 18.43 |
| 3 | Ibuprofen & Paracetamol Suspension | Each 5 ml contains: Ibuprofen IP 100 mg Paracetamol IP 162.5 mg | 1 ml | M/s Shiva Biogenetic Pharmaceuticals Pvt. Ltd. / M/s Mankind Prime Labs Pvt. Ltd. | 0.55 |
| 4 | Dapagliflozin, Glimepiride & Metformin Hydrochloride (ER) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP equivalent to Dapagliflozin 10 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg (as extended release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd. | 10.80 |
| 5 | Dapagliflozin, Glimepiride & Metformin Hydrochloride (ER) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP equivalent to Dapagliflozin 10 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg (as extended release) | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Blue Cross Laboratories Pvt. Ltd. | 11.70 |
| 6 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg Glimepiride IP 1 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Alembic Pharmaceuticals Ltd. | 13.24 |
| 7 | Sitagliptin, Glimepiride & Metformin Hydrochloride Tablets | Each film coated tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 50 mg Glimepiride IP 2 mg Metformin Hydrochloride IP 500 mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Alembic Pharmaceuticals Ltd. | 15.00 |
| 8 | Sitagliptin, Empagliflozin & Metformin Hydrochloride (ER) Tablets | Each film coated bilayer tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Empagliflozin 10 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Macleods Pharmaceuticals Ltd. | 30.00 |
| 9 | Sitagliptin, Empagliflozin & Metformin Hydrochloride (ER) Tablets | Each film coated bilayer tablet contains: Sitagliptin Phosphate Monohydrate IP equivalent to Sitagliptin 100 mg Empagliflozin 25 mg Metformin Hydrochloride (As Extended Release) IP 1000 mg | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Macleods Pharmaceuticals Ltd. | 34.50 |
